Eyepoint Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Eyepoint Pharmaceuticals Inc cash flow-to-debt ratio. Eyepoint Pharmaceuticals Inc (EYPT) has a Cash Flow-to-Debt Ratio of -1.15x as of September 2025, meaning its operating cash flow of $-59.35 Million could theoretically repay -1% of its total liabilities ($51.51 Million) in one year. Check earnings quality score of Eyepoint Pharmaceuticals Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Eyepoint Pharmaceuticals Inc (2002–2024)
Cash flow-to-debt ratio of Eyepoint Pharmaceuticals Inc from 2002 to 2024. Historical debt coverage capacity for Eyepoint Pharmaceuticals Inc across 23 annual periods. Check Eyepoint Pharmaceuticals Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Eyepoint Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2002–2024)
Eyepoint Pharmaceuticals Inc cash flow-to-debt ratio by year from 2002 to 2024. Year-by-year debt coverage analysis for Eyepoint Pharmaceuticals Inc. For the full cash flow conversion analysis, see Eyepoint Pharmaceuticals Inc (EYPT) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.54x | $-126.23 Million | $81.96 Million | ▼ -7398.5% |
| 2023 | 0.02x | $1.88 Million | $88.86 Million | ▲ +102.7% |
| 2022 | -0.77x | $-65.00 Million | $83.99 Million | ▼ -22.0% |
| 2021 | -0.63x | $-50.10 Million | $78.99 Million | ▼ -221.5% |
| 2020 | -0.20x | $-14.44 Million | $73.18 Million | ▲ +77.5% |
| 2019 | -0.88x | $-56.70 Million | $64.64 Million | ▼ -140.2% |
| 2018 | -0.37x | $-21.91 Million | $59.98 Million | ▲ +90.5% |
| 2017 | -3.84x | $-20.49 Million | $5.34 Million | ▼ -152.5% |
| 2016 | -1.52x | $-16.32 Million | $10.74 Million | ▼ -232.8% |
| 2015 | 1.14x | $10.30 Million | $9.00 Million | ▲ +183.1% |
| 2014 | -1.38x | $-10.67 Million | $7.75 Million | ▼ -34.7% |
| 2013 | -1.02x | $-8.74 Million | $8.55 Million | ▲ +20.9% |
| 2012 | -1.29x | $-9.00 Million | $6.96 Million | ▼ -294.9% |
| 2011 | -0.33x | $-3.17 Million | $9.68 Million | ▼ -133.0% |
| 2010 | 0.99x | $9.90 Million | $9.97 Million | ▲ +259.6% |
| 2009 | -0.62x | $-8.44 Million | $13.56 Million | ▼ -110.9% |
| 2008 | -0.29x | $-5.14 Million | $17.44 Million | ▲ +71.9% |
| 2007 | -1.05x | $-21.21 Million | $20.21 Million | ▼ -104.2% |
| 2006 | -0.51x | $-16.14 Million | $31.40 Million | ▲ +91.4% |
| 2005 | -6.01x | $-9.34 Million | $1.56 Million | ▲ +0.0% |
| 2004 | -6.01x | $-9.34 Million | $1.56 Million | ▼ -48.9% |
| 2003 | -4.04x | $-5.44 Million | $1.35 Million | ▲ +22.4% |
| 2002 | -5.20x | $-3.06 Million | $588.38K | — |